Changeflow GovPing Healthcare & Life Sciences Lysando AG Novel Antimicrobial Proteins EP38028...
Routine Rule Added Final

Lysando AG Novel Antimicrobial Proteins EP3802814A1

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

Lysando AG has been granted European Patent EP3802814A1 for novel antimicrobial proteins, published by the EPO on April 15, 2026. The patent application lists inventors Manfred Biebl and Martin Griessl, with IPC classifications covering C12N 9/36 and C07K 14/47. The patent is designated across all EU member states plus associated countries including Switzerland, Norway, and the United Kingdom.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 34 changes logged to date.

What changed

The EPO has published European Patent Application EP3802814A1 for Lysando AG, covering novel antimicrobial proteins. Inventors Manfred Biebl and Martin Griessl are listed, with the application classified under C12N 9/36 and C07K 14/47. The patent designation extends to all EU member states plus associated countries including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Competitors developing similar antimicrobial protein technologies within the EU should review this patent to assess freedom-to-operate implications. The broad designation across nearly all European countries means the patent could affect market entry for competing products throughout the region.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL ANTIMICROBIAL PROTEINS

Publication EP3802814A1 Kind: A1 Apr 15, 2026

Applicants

Lysando AG

Inventors

BIEBL, Manfred, GRIESSL, Martin

IPC Classifications

C12N 9/36 20060101AFI20191206BHEP C07K 14/47 20060101ALI20191206BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Parties

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Manufacturers Investors
Industry sector
3254.1 Biotechnology
Activity scope
Patent examination IP licensing Antimicrobial research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!